IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Targeting FDA regulatory guidance on darovasertib in neoadjuvant UM indication in 2024 Ongoing enrollment of IDE397 and AMG 193 Phase 1 combo in MTAP solid tumors and targeting development of joint Amgen / IDEAYA publication strategy in 2024 Established clinical study collaboration with Gilead Sciences to evaluate IDE397 and Trodelvy® combo in MTAP bladder cancer with FPI targeted for mid-year 2024 Targeting IDE161 clinical program update(s) and enabling of clinical combination(s) in 2024 Targeting Werner IND-filing in 2024 ( $7.0 million milestone upon IND clearance) in collaboration with GSK Targeting multiple wholly-owned next generation development candidate nominations in 2024, including in MTAP, representing 7 or more potential first-in-class programs $632.6 million cash balance as of December 31, 2023 , supplemented by net proceeds of .3 million from January 2024 ATM offerings, expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif. Feb. 20, 2024 /PRNew
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyPR Newswire
- IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerPR Newswire
IDYA
Earnings
- 5/9/23 - Beat
IDYA
Sec Filings
- 4/24/24 - Form ARS
- 4/19/24 - Form DEF
- 3/12/24 - Form 8-K
- IDYA's page on the SEC website